Responsibilities

Michael Davenport is executive director of clinical pharmacology and biostatistics for Furiex. His areas of responsibility include clinical pharmacology, biostatistics, data management, and bioanalytical and central laboratory services.

Dr. Davenport has more than 25 years of diverse clinical, preclinical, drug research and development, and device manufacturing experience for both small and large pharmaceutical companies. For the past 15 years, he has gathered extensive experience in the pharmacokinetic aspects of drug development.

Prior to joining Furiex, Dr. Davenport was senior director of clinical pharmacology at PPD. In addition to managing the operational activities of the clinical pharmacology department, he provided development strategies to PPD clients (including protocol design and analytical strategies) as well as pharmacokinetic support in interpretation of the relevance and significance of pharmacokinetic observations, data and parameters. In his role, he also handled Phase I clinical pharmacology reports and consulting services for drug development programs, and statistical design and analysis of experiments for IND, ANDA and NDA submissions, along with multiple other tasks.

Education

Dr. Davenport earned a bachelor’s degree in mathematics and a master’s degree in statistics from the University of Arkansas and a doctorate in biostatistics from the Virginia Commonwealth University.